CONMED Q4 Earnings: Orthopedics Surge, Supply Chain Improvements, and Strategic Focus on Growth

[Para 1] CONMED's Q4 earnings saw a robust performance, particularly in its orthopedics division, marking a significant market impact. The company's strategic pivot away from lower-growth gastroenterology products and focus on high-growth areas like robotic surgery and orthopedic soft tissue repair is driving financial gains. Shares of CONMED (CNMD) closed at $38.80, unchanged from pre-earnings trading at $38.69. [Para 2-3] Management highlighted a three-year low in backorder values and SKUs, attributing this to improved sports medicine supply, successful product launches, and strong sales team execution. Analysts are now focusing on the pace of adoption for CONMED's AirSeal and BioBrace platforms, the company's supply chain resilience, and potential M&A activity. The market is watching for signals on margin impacts from tariffs and the successful transition of CFO responsibilities.